Literature DB >> 19059906

The role of oxidized phospholipids in atherosclerosis.

Judith A Berliner1, Norbert Leitinger, Sotirios Tsimikas.   

Abstract

There is increasing evidence that oxidized phospholipids (OxPLs) play an important role in atherosclerosis. These phospholipids accumulate in human and mouse lesions. Specific OxPLs have been identified as major regulators of many cell types present in the vessel wall. In endothelial cells, >1,000 genes are regulated. Some of these genes are pro-atherogenic and others anti-atherogenic. The anti-atherogenic effects are likely important in slowing the atherogenic process. Several receptors and signaling pathways associated with OxPL action have been identified and shown to be upregulated in human lesions. A structural model of the mechanism by which specific OxPLs serve as CD36 ligands has been identified. Specific oxidized phospholipids are also present in plasma and associated with Lp(a) particles. In humans, OxPL/apolipoprotein B has been shown to be a prognostic indicator and a separate risk factor for coronary events. Levels of OxPL in plasma have been shown to be correlated with platelet activation. The results of these studies suggest an important role for OxPL in all stages of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19059906      PMCID: PMC2674746          DOI: 10.1194/jlr.R800074-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  48 in total

1.  Vascular endothelial growth factor receptor 2 plays a role in the activation of aortic endothelial cells by oxidized phospholipids.

Authors:  Alejandro Zimman; Kevin P Mouillesseaux; Thang Le; Nima M Gharavi; Ann Ryvkin; Thomas G Graeber; Tom T Chen; Andrew D Watson; Judith A Berliner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-11-16       Impact factor: 8.311

Review 2.  Lipoprotein(a): a unique risk factor for cardiovascular disease.

Authors:  Erdembileg Anuurad; Michael B Boffa; Marlys L Koschinsky; Lars Berglund
Journal:  Clin Lab Med       Date:  2006-12       Impact factor: 1.935

3.  Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells.

Authors:  Yury I Miller; Suganya Viriyakosol; Christoph J Binder; James R Feramisco; Theo N Kirkland; Joseph L Witztum
Journal:  J Biol Chem       Date:  2002-11-06       Impact factor: 5.157

4.  Reduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice.

Authors:  Brenda R Kwak; Niels Veillard; Graziano Pelli; Flore Mulhaupt; Richard W James; Marc Chanson; François Mach
Journal:  Circulation       Date:  2003-02-25       Impact factor: 29.690

5.  Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization.

Authors:  Véronique Angeli; Jaime Llodrá; James X Rong; Kei Satoh; Satoshi Ishii; Takao Shimizu; Edward A Fisher; Gwendalyn J Randolph
Journal:  Immunity       Date:  2004-10       Impact factor: 31.745

6.  Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells.

Authors:  J M Heery; M Kozak; D M Stafforini; D A Jones; G A Zimmerman; T M McIntyre; S M Prescott
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

7.  Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2.

Authors:  Kimberly A Walton; Amy L Cole; Michael Yeh; Ganesamoorthy Subbanagounder; Stephan R Krutzik; Robert L Modlin; Robert M Lucas; Junko Nakai; Eric J Smart; Deven K Vora; Judith A Berliner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-05-29       Impact factor: 8.311

8.  Epoxycyclopentenone-containing oxidized phospholipids restore endothelial barrier function via Cdc42 and Rac.

Authors:  Konstantin G Birukov; Valery N Bochkov; Anna A Birukova; Kamon Kawkitinarong; Alexander Rios; Alexander Leitner; Alexander D Verin; Gary M Bokoch; Norbert Leitinger; Joe G N Garcia
Journal:  Circ Res       Date:  2004-10-07       Impact factor: 17.367

9.  Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids.

Authors:  J D Morrow; J A Awad; H J Boss; I A Blair; L J Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

10.  Dyslipidemia inhibits Toll-like receptor-induced activation of CD8alpha-negative dendritic cells and protective Th1 type immunity.

Authors:  Abdijapar T Shamshiev; Franziska Ampenberger; Bettina Ernst; Lucia Rohrer; Benjamin J Marsland; Manfred Kopf
Journal:  J Exp Med       Date:  2007-02-12       Impact factor: 14.307

View more
  84 in total

Review 1.  Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

Authors:  Robert S Rosenson; Diana M Stafforini
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

2.  Lysophosphatidic acid effects on atherosclerosis and thrombosis.

Authors:  Mei-Zhen Cui
Journal:  Clin Lipidol       Date:  2011-08

3.  Metalloproteinase processing of HBEGF is a proximal event in the response of human aortic endothelial cells to oxidized phospholipids.

Authors:  Sangderk Lee; James R Springstead; Brian W Parks; Casey E Romanoski; Roland Palvolgyi; Tiffany Ho; Phuc Nguyen; Aldons J Lusis; Judith A Berliner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03-08       Impact factor: 8.311

4.  Naturally occurring human plasminogen, like genetically related apolipoprotein(a), contains oxidized phosphatidylcholine adducts.

Authors:  Celina Edelstein; Ditta Pfaffinger; Ming Yang; John S Hill; Angelo M Scanu
Journal:  Biochim Biophys Acta       Date:  2010-03-24

5.  Reductive metabolism increases the proinflammatory activity of aldehyde phospholipids.

Authors:  Elena Vladykovskaya; Evgeny Ozhegov; J David Hoetker; Zhengzhi Xie; Yonis Ahmed; Jill Suttles; Sanjay Srivastava; Aruni Bhatnagar; Oleg A Barski
Journal:  J Lipid Res       Date:  2011-09-27       Impact factor: 5.922

6.  Paraoxonase-2 modulates stress response of endothelial cells to oxidized phospholipids and a bacterial quorum-sensing molecule.

Authors:  Juyong Brian Kim; Yu-Rong Xia; Casey E Romanoski; Sangderk Lee; YongHong Meng; Yi-Shou Shi; Noam Bourquard; Ke Wei Gong; Zachary Port; Victor Grijalva; Srinivasa T Reddy; Judith A Berliner; Aldons J Lusis; Diana M Shih
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11       Impact factor: 8.311

Review 7.  Regulation of platelet function by class B scavenger receptors in hyperlipidemia.

Authors:  Alejandro Zimman; Eugene A Podrez
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

Review 8.  Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.

Authors:  Adam Taleb; Joseph L Witztum; Sotirios Tsimikas
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

9.  Fatty acid epoxyisoprostane E2 stimulates an oxidative stress response in endothelial cells.

Authors:  Xinmin Yan; Sangderk Lee; B Gabriel Gugiu; Lukasz Koroniak; Michael E Jung; Judith Berliner; Jinluo Cheng; Rongsong Li
Journal:  Biochem Biophys Res Commun       Date:  2014-01-14       Impact factor: 3.575

Review 10.  Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis.

Authors:  Sotirios Tsimikas
Journal:  Circ Res       Date:  2019-02       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.